국내 남성에서 포스포디에스테라제 5형 억제제 불법유통 사용현황, 안전성 및 관련 요인
Utilization, Safety, and Related Factors of Illegal Phosphodiesterase Type 5 Inhibitors in South Korean Men
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Phosphodiesterase Type 5 Inhibitors (PDE5Is), which are prescription drug in South Korea, have been concernedabout misuse, overuse and illegal provision of the drugs. This study was performed to investigate utilization and safety of illegalPhosphodiesterase Type 5 Inhibitors (PDE5Is), and related factors among South Korean men. Methods: A questionnaire survey wasconducted from May to July in 2013 among 1,500 nationally representative general males using computer-assisted telephoneinterview (CATI). The questionnaire included the characteristics of population, the characteristics of PDE5Is use, the experience withthe use of illegally obtained PDE5Is, and adverse events after PDE5Is use. Results: Among study population, the 1,015 (67.7%) menanswered that they have used the illegally obtained PDE5Is. Younger age, single, lower frequency of PDE5Is use in a lifetime wasassociated with an increased use of illegally obtained PDE5Is. The men experienced adverse events after PDE5Is use is 528(35.2%). The most common adverse event was mild to moderate hot flashes. Conclusion: We need to enhance awareness aboutthe risk of illegally obtained PDE5Is use, especially in younger men and single. Proactive educations and public relations on safeuse of PDE5Is for proper patients are needed.
Abstract
Background: Phosphodiesterase Type 5 Inhibitors (PDE5Is), which are prescription drug in South Korea, have been concernedabout misuse, overuse and illegal provision of the drugs. This study was performed to investigate utilization and safety of illegalPhosphodiesterase Type 5 Inhibitors (PDE5Is), and related factors among South Korean men. Methods: A questionnaire survey wasconducted from May to July in 2013 among 1,500 nationally representative general males using computer-assisted telephoneinterview (CATI). The questionnaire included the characteristics of population, the characteristics of PDE5Is use, the experience withthe use of illegally obtained PDE5Is, and adverse events after PDE5Is use. Results: Among study population, the 1,015 (67.7%) menanswered that they have used the illegally obtained PDE5Is. Younger age, single, lower frequency of PDE5Is use in a lifetime wasassociated with an increased use of illegally obtained PDE5Is. The men experienced adverse events after PDE5Is use is 528(35.2%). The most common adverse event was mild to moderate hot flashes. Conclusion: We need to enhance awareness aboutthe risk of illegally obtained PDE5Is use, especially in younger men and single. Proactive educations and public relations on safeuse of PDE5Is for proper patients are needed.
참고문헌 (21)
- NIH Consensus Development Panel on Impotence, "NIH Consensus Conference : impotence", JAMA, 270, pp.83~90 (1993)
- Feldman HA., "Impotence and its medical and psychosocial correlates : results of the Massachusetts Male Aging Study", J Urol, 151, pp.54~61 (1994)
- Sánchez-Cruz JJ., "Male erectile dysfunction and health related quality of life", Eur Urol, 44, pp.245~253 (2003)
- Rajfer J., "Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission", N Engl J Med, 326, pp.90~94 (1992)
- "Ministry of Food and Drug Safety" (2012)[URL]
- Yang SK., "KSSMA eradication campaign for counterfeit PDE5I", Kor J Androl 18th conference (2012)
- Kao SL., "An unusual outbreak of hypoglycemia", N Engl J Med, 360, pp.734~736 (2009)
- Department of Health of the Government of the Hong Kong Special Administrative Region, "Public urged not to consume capsules for treating sexual dysfunction with undeclared drug" (2008), Press Release
- Ministry of Food and Drug Safety., "Regulation on potential misuse and abuse drugs", 12~ (2014)
- Ministry of Food and Drug Safety., "Drug Safety Use Manual 22. Oral Phosphodiesterase Type 5 Inhibitors", ~ (2013)
- 김민수, "다종의 경구용 발기부전치료제 시대를 맞아 대학병원을 찾는 발기부전환자의 발기부전치료에 대한 인식도", The World Journal of Men's Health, 24(1), pp.18~22 (2006), 대한남성과학회
- Jackson G., "Cardiovascular safety of sildenafil citrate(Viagra) : an updated perspective", Urology, 68, pp.47~60 (2006)
- Carson CC., "The efficacy of sildenafil citrate(Viagra)in clinical populations : an update", Urology, 60, pp.12~27 (2002)
- Banks I., "Assessment, in a General Population of men, of Men’s Interaction With the Healthcare System to Obtain Phosphodiesterase Type 5 Inhibitors", Joint Congress of the European and International Societies for Sexual Medicine (2008)
- Schnetzler G., "Characteristics, behaviors, and attitudes of men bypassing the healthcare system when obtaining phosphodiesterase type 5 inhibitors", J Sex Med, 7, pp.1237~1246 (2010)
- Korean Society for Sexual Medicine and Andrology, "Fake Phosphodiesterase Type 5 Inhibitors Status", 10, pp.26~29 (2012)
- 김세철, "발기부전 환자와 배우자의 성 태도와 치료에 대한 인식", The World Journal of Men's Health, 27(1), pp.1~9 (2009), 대한남성과학회
- "Micromedex"[URL]
- 양철수, "Phosphodiesterase 5형 억제제의 부작용이 약물 선택에 미치는 영향", Investigative and Clinical Urology, 47(3), pp.272~278 (2006), 대한비뇨기과학회
- Lowe G, "10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors", J Sex Med, 9, pp.265~270 (2012)
- "Ministry of Food and Drug Safety" (2014)[URL]